Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death
risk and strategy stratification are lacking. In this setting, a simple biological scoring
system have recently been proposed, including LDH and CD138 binary status seric values,
identifying one third of patients with worst prognostic.
Intensified-chemotherapy strategies, combining 5-fluorouracile, Oxaliplatin, Irinotecan and
Bevacizumab, are beneficial for patients having a bad prognostic, defined by the BRAFV600E
mutation, concerning 5-8% of first line mCRC.
For the 30% of patients with LDH-CD138 elevated score, the purpose of CLavSyn phase II study
is to compare the PFS of one intensified arm (FOLFOXIRI Bevacizumab) to one standard
chemotherapy arm, in order to better discriminate treatment strategies, at metastatic
diagnosis.